Payment overview · 2025
General Payments
$1,785.07
82 reported records · 23 companies
Healthcare provider profile · identity verified
Ahmad Daif
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CHICAGO, IL · NPI 1326459553
Verified facts
What the public records show
CMS Open Payments records show Ahmad Daif received $1,785.07 in general payments during 2025 across 82 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $279.12 | 15.6% | 11 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $200.81 | 11.2% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $172.38 | 9.7% | 12 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $151.70 | 8.5% | 6 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $147.23 | 8.2% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $85.36 | 4.8% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $71.72 | 4.0% | 3 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.78 | 3.9% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$62.89 | 3.5% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $60.61 | 3.4% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $58.91 | 3.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.46 | 3.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $54.53 | 3.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $52.97 | 3.0% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $43.36 | 2.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.63 | 2.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.24 | 2.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.31 | 1.8% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $24.25 | 1.4% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $24.21 | 1.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.62 | 1.2% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $15.59 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.39 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,712.57 | 81 |
| Education | $72.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $206.62 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $151.70 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $147.23 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $147.23 | 6 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $101.63 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $94.54 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.54 | 7 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $85.36 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $84.23 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $79.69 | 5 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $71.72 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $62.89 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $60.96 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $60.61 | 3 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $58.91 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $56.46 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $56.46 | 3 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $54.53 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $52.97 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $31.75 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 37 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 363 | 149 |
| Gabapentin | Gabapentin | 286 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 76 |
| Levetiracetam | Levetiracetam | 163 | 50 |
| Donepezil Hcl | Donepezil Hcl | 140 | 42 |
| Furosemide | Furosemide | 133 | 49 |
| Memantine Hcl | Memantine Hcl | 114 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 109 | 43 |
| Lisinopril | Lisinopril | 96 | 28 |
| Losartan Potassium | Losartan Potassium | 94 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 88 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 38 |
| Eliquis | Apixaban | 84 | 37 |
| Pregabalin | Pregabalin | 81 | 32 |
| Carvedilol | Carvedilol | 77 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 23 |
| Trazodone Hcl | Trazodone Hcl | 74 | 29 |
| Oxcarbazepine | Oxcarbazepine | 73 | 42 |
| Omeprazole | Omeprazole | 70 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 21 |
| Mirtazapine | Mirtazapine | 62 | 20 |
| Sertraline Hcl | Sertraline Hcl | 61 | 25 |
| Metformin Hcl | Metformin Hcl | 56 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 26 |
| Clonazepam | Clonazepam | 51 | 25 |
| Famotidine | Famotidine | 47 | 18 |
| Nifedipine Er | Nifedipine | 47 | 15 |
| Xarelto | Rivaroxaban | 47 | 11 |
| Tramadol Hcl | Tramadol Hcl | 46 | 28 |
| Lamotrigine | Lamotrigine | 45 | 14 |
| Potassium Chloride | Potassium Chloride | 44 | 17 |
| Baclofen | Baclofen | 42 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 17 |
| Topiramate | Topiramate | 38 | 13 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 14 |
| Simvastatin | Simvastatin | 35 | 14 |
| Primidone | Primidone | 32 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 32 | 11 |
| Nystatin | Nystatin | 31 | 11 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 12 |
| Meloxicam | Meloxicam | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | 11 |
| Ezetimibe | Ezetimibe | 26 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 11 |
| Enalapril Maleate | Enalapril Maleate | 21 | 11 |
| Glipizide | Glipizide | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Fluconazole | Fluconazole | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,785.07 · 82 records | Teva Pharmaceuticals USA, Inc. | AMYVID, AUSTEDO XR, BOTOX, ENTYVIO, Fintepla, INFINITY, INGREZZA, JOURNAVX, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus, Ocrevus Zunovo, QULIPTA, QUTENZA, REXULTI, Rystiggo, UBRELVY, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYEPTI, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error